EIF4EBP3 and breast cancer: For instance, miR-22-3p delivered by bone marrow mesenchymal stem cell-derived extracellular vesicles can promote osteogenic differentiation.43 Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular anomalies to promote tumor budding in breast cancer.44 Additionally, miR-22-3p inhibits cell apoptosis through targeting eIF4EBP3 in cervical squamous carcinoma cells.45 These are consistent with our observation that inhibition of miR-22-3p predisposes cancer cells to death.